Card image cap
FDA approves Nasonex for OTC use

The US Food and Drug Administration has approved mometasone furoate monohydrate, an intranasal corticosteroid nasal spray designed to treat and prevent hay fever and allergy symptoms, for over-the-counter use. Perrigo Company Plc, which owns the brand –Nasonex– said it expects to begin offering the nasal spray (Nasonex 24HR Allergy) as an OTC product later this year. This first prescription-to-OTC switch for Nasonex represents access to self-care products to a large patient population, who need the rescue inhalers/sprays in allergy and respiratory related emergency conditions.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment